Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
BioSpace
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.
Novo’s late-stage sickle cell win piles pressure on competitors
BioSpace
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday.
S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer
OncLive Podcast
In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A.
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Pharmaceutical Technology
Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
FDA Policy Tracker 2026: Psychedelics get a boost
BioSpace
A year of significant policy change at the FDA brought momentum and scrutiny into the new year.
UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator
Pharmaphorum
Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI ML in the UK.
Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia
Pharmaphorum
Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
The Omnichannel Gap: Building the CRM of the Future for Patient Services
Drug Channels
Today’s guest post comes from Karishma Desai, Associate Director of Data Strategy at Claritas Rx.
AZ is three for three with COPD hope tozorakimab
Pharmaphorum
AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.
Trump backs psychedelics for mental health in new executive order
Pharmaceutical Technology
Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.
UCB to purchase Neurona and NRTX-1001 for $1.15bn
Pharmaceutical Business Review
The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Pharmaceutical Business Review
This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.
UCB to purchase Neurona and NRTX-1001 for $1.15bn
Pharmaceutical Technology
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.
UCB cuts $1.15bn deal to buy epilepsy biotech Neurona
Pharmaphorum
UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
Magazine: Digital twins become the new battleground for CDMOs
Pharmaceutical Technology
In this issue: CDMOs use of digital twins to realise a strategic advantage, Physical AI’s rise in pharma manufacturing, and more.
What actually drives speed in complex drug development programs
BioPharma Dive
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.
Trump signs order to hasten psychedelic medicine access
Pharmaphorum
Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
Kailera makes history with record-breaking $625m IPO
Pharmaceutical Technology
Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
BioPharma Dive
Some 1,390 Foundayo prescriptions were written in two days, according to analysts.
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
BioSpace
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given